{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-003796","form_type":"8-K","ticker":"PMCB","cik":"0001157075","company_name":"PharmaCyte Biotech, Inc.","filed_at":"2024-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.473666+00:00","generated_at":"2026-06-01T09:03:57.315015+00:00","sec_items":["1.01","2.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PharmaCyte invests $7M in MyMD for convertible preferred stock and warrants","bullets":["Invests $7M for Series G Convertible Preferred Stock convertible into 3,854,626 MyMD common shares at $1.816 per share.","Also receives warrants to purchase up to 3,854,626 MyMD common shares (5-year and 18-month terms) at $1.816 per share.","Gets right to nominate one board member while owning >20% of MyMD common stock on as-converted basis.","MyMD filed Certificate of Designations for Series G Preferred with 10% annual dividend, compounded monthly.","MyMD is a clinical-stage biopharma with Phase 2 data in sarcopenia (MYMD-1) and advancing toward FDA discussions."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-003796","json":"https://secwatch.observer/filing/0001683168-24-003796.json","markdown":"https://secwatch.observer/filing/0001683168-24-003796.md","text":"https://secwatch.observer/filing/0001683168-24-003796.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157075/000168316824003796/0001683168-24-003796-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157075/000168316824003796/pharmacyte_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:03:57.315015+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}